Today's Rundown Sanofi, Alnylam officially end their RNA pact as Regeneron jumps in United Therapeutics tosses out esuberaprost after trial flop Trevi Therapeutics jumps on the biotech IPO train [Sponsored] The Power to Pivot: Using Dedicated Onsite Resources to Adapt Recruitment Practices in a Shifting Landscape U.K. biotech Kymab nabs new CEO from Merck KGaA Allergan's failed depression drug shows promise in opioid withdrawal Pricing a hurdle for next-gen devices, but Canadian robotics company says change is coming Special Report—The top 15 pharma companies by 2018 revenue Featured Story | | | Monday, April 8, 2019 Over the past year, Sanofi and Alnylam have been retooling their 2014 R&D pact around Alnylam's RNA tech; today, the pair signaled its end, and former Sanofi partner Regeneron has stepped in. |
|
|
| This week's sponsor is Deloitte. | | | Deloitte's 2019 Life Sciences accounting and financial reporting update
Insights on new accounting standards and more
A year of major change for life sciences companies is underway. Deloitte's latest update on life sciences financial reporting explains what accounting departments need to know to keep up in a rapidly evolving environment. Download the full report here. |
Top Stories Monday, April 8, 2019 United Therapeutics is throwing its pulmonary arterial hypertension drug esuberaprost on the scrap heap after failing in a phase 3 test. Monday, April 8, 2019 Who isn’t gunning for a biotech initial public offering these days? We thought that maybe after Moderna’s monster raise last year we had reached a peak, but the window remains open, and Trevi is the latest biotech to jump on through. Monday, April 8, 2019 Increasingly complex trials place a burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Strategically placed Enrollment Assistants can ease that burden, making sites more agile and offering patients personalized attention that leads to conversion and retention. Monday, April 8, 2019 Kymab has hired on a new CEO, Simon Sturge, to usher the antibody specialist into its next phase of growth. Sturge joins from Merck KGaA, where he oversaw the launches of cancer drugs Bavencio and Mavenclad for multiple sclerosis. Sunday, April 7, 2019 Allergan's rapastinel, the centerpiece of its $560 million acquisition of Naurex, recently failed in pivotal trials in depression. But scientists at Duke University and Villanova University may have found another use for the drug: to aid in opioid withdrawal. Friday, April 5, 2019 “The economic and mathematical model must be changed to analyze [payers’] involvement. ... But it will happen within some years, for sure. So we just need to survive until then,” said Stéphane Bédard, CEO of B-Temia, a Quebec City-based company developing what it calls dermoskeletic devices to assist human mobility. Monday, April 8, 2019 The big names always turn up near the top of yearly sales rankings, and this year is no different. Many companies on this list have faced big patent losses in recent years, while some have big launches coming up, too. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: Data MATRIX | 3:00 AM EDT / 9:00 AM EDT / 2:00 PM EDT How to cut a study budget by 4 times? How to process CRFs 3 times faster? What made a CRO switch from a US vendor to Data MATRIX? In 45 minutes, we will dissolve myths about entering the market. Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 